[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nervous-system-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nervous-system-diseases":33},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,51,108,139,172,256,338,372,410,444,494,523,548,569,587,618,648,679,731,759,791,844,865,900,919],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100525407","precision-medicine-in-stroke-evolution-of-plasma-brain-derived-tau-in-acute-stroke-100525407",false,"NCT06121336","PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke","PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke","PROMISE-BD-100","Inclusion Criteria:\n\n* clinical diagnosis of acute ischemic stroke\n* presentation within 9 hours of symptom onset\n* large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \\[segments M1-M4\\], ACA \\[segments A1-A3\\], basilar artery, or PCA \\[segments P1 to P3\\]) confirmed by CT or MRI angiography\n* at least 18 years of age\n* written informed consent\n\nExclusion Criteria:\n\n* CT or MRI showing intracranial hemorrhage upon admission\n* A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months\n* dementia\n* pre-stroke disability defined as a premorbid modified Rankin Scale score \\> 2","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.",[26,27,28,29,30,31,32,33],"Stroke","Stroke, Acute","Stroke, Ischemic","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Brain Ischemia","Nervous System Diseases",[26,35,36,37],"Brain injury","Biomarker","Pathophysiology","RECRUITING","2026-08-19",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":42},"2023-03-01",{"date":46,"type":22},"2027-03-31",{"name":48,"class":49},"Ludwig-Maximilians - University of Munich","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":82,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100638788","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-aoc-1044-also-referred-to-as-delpacibart-zotadirsen-in-participants-with-dmd-with-gene-mutations-amenable-to-exon-44-skipping-100638788","NCT07587242","A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping","SAFARI44","Key Inclusion Criteria:\n\n* Ambulatory males with clinical and genetic diagnosis of DMD\n* Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping\n* 7 to 16 years of age at time of consent\n* TTR and NSAA assessment completed within the protocol specified parameters at Screening\n* On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.\n\nKey Exclusion Criteria:\n\n* Previous treatment cell or gene therapy.\n* Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).\n* Lab values outside of the protocol specified range at Screening\n* If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:\n* Less than 1 month, for growth hormone and\u002For testosterone\n* Less than 6 months for givinostat","MALE","7 Years","16 Years",{"count":63,"type":22},70,"INTERVENTIONAL",[66],"PHASE3","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping",[69,70,71,72,73,74,33,75,76,77,78,79,80,81],"Muscular Dystrophies","Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)","Muscular Disorders, Atrophic","Muscular Disease","Musculoskeletal Diseases","Neuromuscular Diseases (NMD)","Genetic Diseases","X-Linked","Hereditary","Neonatal Disease","Duchene Muscular Dystrophy","Congenital","DMD",[83,84,85,86,87,88,89,90,57,91,92,93,94,95,96,81],"AOC","AOC 1044","AOC 1044-CS3","AOC 1044-CS1","AOC 1044-CS2","EXPLORE44","EXPLORE44-OLE","SAFARI","SAFARI 44","Avidity","Avidity Biosciences","Exon Skipping Therapy","Avidity Biosciences Inc., A Novartis Company","del-zota","2026-08-14",{"date":99,"type":42},"2026-08-17",{"date":101,"type":22},"2026-08",{"date":103,"type":22},"2030-07",{"name":105,"class":106},"Avidity Biosciences, Inc.","INDUSTRY",11,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":64,"phases":118,"briefSummary":120,"conditions":121,"keywords":129,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":50},"100651456","music-4-ms-to-improve-cognition-in-people-living-with-multiple-sclerosis-a-feasibility-study-100651456","NCT07759115","Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study","A Randomized Controlled Trial of Music-4-MS Compared to Music Listening to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study","Inclusion Criteria:\n\n* Diagnosed with multiple sclerosis (relapsing remitting, secondary progressive, primary progressive)\n* Diagnosed more than 6 months prior to starting study\n* Self-reported cognitive impairment as assessed by having at leased 5 problems \"sometimes\" or more often on the Perceived Deficits Questionnaire\n* Read, write, and understand English\n* Access to internet\n\nExclusion Criteria:\n\n* Diagnosed with another neurological condition that causes cognitive impairment\n* MS exacerbation within the last 30 days\n* Professional musician (primary source of income)","80 Years",{"count":117,"type":22},64,[119],"NA","Multiple sclerosis (MS) rates in the U.S. have nearly doubled over the past decade, making it a leading cause of nontraumatic functional impairment in young adults and significantly affecting cognitive function in up to 70% of people with MS. While traditional cognitive rehabilitation methods are limited in sensory engagement, music training offers a multisensory approach that enhances neuroplasticity and improves cognitive functions. This study investigates the feasibility of Music-4-MS, a 12-week music-based eHealth intervention, to support cognitive and emotional health in individuals with MS.",[122,123,124,125,33,126,127,128],"Multiple Sclerosis","Pathologic Processes","Demyelinating Autoimmune Diseases, CNS","Autoimmune Diseases of the Nervous System","Demyelinating Diseases","Autoimmune Diseases","Immune System Diseases",[130],"Cognitive rehabilitation","2026-08-13",{"date":99,"type":42},{"date":134,"type":42},"2026-08-10",{"date":136,"type":22},"2028-08",{"name":138,"class":49},"University of Texas at Austin",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":59,"minAge":146,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":155,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":170,"locationsCount":171},"100612219","managed-access-program-for-del-zota-in-participants-with-dmd-mutations-amenable-to-exon-44-skipping-100612219","NCT07250737","Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping","Key Inclusion Criteria\n\nRollover Participants\n\n* Completed Study EXPLORE44-OLE Treatment Period (through W102)\n* No significant tolerability issues with AOC 1044\n\nNew (Non-Rollover) Participants\n\n* Permanently residing in the US and have a US primary health care provider\n* Documented dystrophin gene mutation that is amenable to exon 44 skipping\n* Age 2 or older at the time of consent\n* If previously treated with gene therapy for DMD, treatment and associated immunosuppressive regimen was more than 12 months before consent and in the opinion of the prescriber, participant has had an unsatisfactory treatment response\n\nKey Exclusion Criteria\n\nRollover Participants\n\n• Prescence of any new condition or worsening of existing condition that could affect participant's safety or ability to comply with the program requirements\n\nNew (Non-Rollover) Participants\n\n* Recently treated with or on a clinical study for another investigation drug\n* Serious respiratory or cardiac dysfunction, or nearing end of life\n* Screening laboratory parameters do not meet protocol requirements\n* History of multiple drug allergies or to any component of AOC 1044\n* Participants who discontinued early from the treatment period of EXPLORE44 or EXPLORE44-OLE","2 Years","EXPANDED_ACCESS","The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.",[71,150,73,151,33,152,153,69,154],"Muscular Diseases","Neuromuscular Diseases","Genetic Diseases, Inborn","Genetic Diseases, X-Linked","Muscular Dystrophy, Duchenne",[92,93,84,86,87,88,89,156,157,81,158,159,160,161,162,163,164,165],"Del-zota","delpacibart zotadirsen","exon skipping therapy","dystrophin","managed access","expanded access","pre-approval access","compassionate use","MAP","EAP","AVAILABLE","2026-08-11",{"date":169,"type":42},"2026-08-12",{"name":105,"class":106},19,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":59,"minAge":19,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":64,"phases":182,"briefSummary":184,"conditions":185,"keywords":199,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":255},"100650026","phase-2-testosterone-therapy-with-or-without-finasteride-after-spinal-cord-injury-trt-sci-trial-100650026","NCT07742553","Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","A Multisite, Double-blind, Randomized Controlled Trial Comparing Body Composition, Muscle, and Bone Changes to TestosteRone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial","TRT-SCI","Inclusion Criteria:\n\n* Veterans eligible for care within the Veterans Health Administration (VHA)\n* Diagnosis of motor incomplete SCI (AIS C-D) for \\>24-months involving spinal segment lumbar (L)1 or above from trauma, vascular, or orthopedic pathology\n* Low total testosterone (\\\u003C300 nanograms\u002Fdecilliter \\[ng\u002FdL\\]) and\u002For low free testosterone (\\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign of low testosterone, defined as:\n\n  * decreased energy\n  * motivation\n  * initiative or self-confidence\n  * increased fatigue or tiredness\n  * reduced sexual desire or activity\n  * decreased spontaneous (e.g., morning) erections or erectile dysfunction\n  * loss of body hair or reduced shaving\n  * feeling sad or blue or having a depressed mood or a persistent low-grade depressive disorder (defined as a score of \\>3 on the Patient Health Questionnaire \\[PHQ\\]-2)\n  * hot flashes\n  * fatigue or irritability\n  * poor concentration or memory\n  * mild unexplained (normocytic-normochromic) anemia, defined as hematocrit (HCT) \\\u003C40%, hemoglobin \\\u003C13.6 grams\u002Fdeciliter (g\u002FdL), or red blood cell count \\\u003C4.5 million\u002Fmicroliter (mcL)\n  * sleep disturbances or increased sleepiness\n  * reduced muscle bulk, strength, or physical function\n  * increased body fat or body mass index\n* Presence of motor impairment, defined as self-selected walking pace ≤1.0 meters\u002Fsecond (m\u002Fs) on a 10-meter walk test (10mWT), with or without gait devices or braces and with or without assistance from another person, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairment identified by a trained observer\n* Medically stable condition asymptomatic for bladder infection, major decubiti, cardiopulmonary disease, or other significant condition that will interfere with the study\n* Documented approval from a physician verifying medical status\n\nExclusion Criteria:\n\n* Involvement in another research study that may influence outcomes\n* Mental state that precludes understanding the protocol\n* Life expectancy \\\u003C12 months\n* History of or current congenital spinal cord injury (SCI) (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Friedreich's ataxia) or degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate procedures\n* Amyotrophic lateral sclerosis, multiple sclerosis, or other neurologic injury \u002F impairment that may complicate procedures\n* Current cancer diagnosis\n* History of prostate or breast cancer\n* Any diagnosed or treated cancer in the past 24 months, except basal or squamous cell carcinoma of the skin that has been successfully treated\n* Any major lower-limb fracture in the past 12 months\n* Unevaluated circulating prostate-specific antigen (PSA) \\>4.0 nanograms\u002Fmilliliter (ng\u002FmL) or \\>3.0 ng\u002FmL in men with prostate cancer risk factors, including agent orange exposure, first degree relative with prostate cancer, or African American background\n* Currently seeking fertility or expected during the study\n* Diagnosed gynecomastia\n* Hematocrit (HCT) \\>48%\n* Any major cardiovascular event in the last 6 months, defined as:\n\n  * an acute myocardial infarction\n  * any cardiac revascularization procedure including stenting\n  * angioplasty or coronary artery bypass grafting\n  * revascularization of the carotid or middle cerebral artery or procedure to treat critical limb ischemia\n  * hospitalization due to unstable angina\n  * transient ischemic attack\n  * stroke\n  * peripheral vascular disease\n* Any angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV)\n* Poorly controlled hypertension when on medication (consistent systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg)\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram findings such as left bundle branch block or marked abnormality that precludes serial screening for occult ischemic events\n* History of unprovoked deep venous thrombosis, unprovoked pulmonary embolism, history of recurrent deep venous thrombosis or known thrombophilia\n* Major non-cardiovascular surgery (e.g., major abdominal or thoracic procedure) within 90 days before screening or a major surgery scheduled at the time of screening\n* Liver enzymes (aspartate aminotransferase \\[AST\\] or alanine aminotransferase \\[ALT\\]) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease defined as eGFR \\\u003C30 milliliters\u002Fminute (mL\u002Fmin)\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Use of an agent that alters sex-steroid metabolism in the past 90 days, such as: testosterone therapy (TRT), compounded or over-the-counter androgenic hormone or androgen precursor, 5-alpha reductase (5AR) inhibitors, growth hormone, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or others\n* Use of anti-resorptive or bone anabolic drug therapy in the past 180 days\n* Acute use (\\>5 days) of any opioid (e.g., oxycodone, hydrocodone) or systemic glucocorticoids \\>7.5 milligrams (mg)\u002Fday prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) in the week before screening, except for men who are taking these for a chronic condition and who are anticipated to continue these for the study duration\n* Known allergy to any TRT component (e.g., cottonseed oil or other)\n* Any other condition, lab abnormality, therapy, medical or psychiatric condition, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive a study intervention, or interfere with their ability to participate for the full study duration",{"count":181,"type":22},300,[183,66],"PHASE2","Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life. These deficits result from reduced activity after SCI and may be worsened by low testosterone, which is present in many men with SCI. In older men with low testosterone who do not have SCI, testosterone therapy (TRT) is known to increase muscle mass, muscle strength, and bone mineral density, and to reduce body fat. However, it is not known if TRT is effective in men with SCI. The purposes of this study are to determine the effectiveness of TRT in men who have low testosterone and difficulty walking after chronic motor incomplete SCI and to assess whether a process in the body that changes testosterone to dihydrotestosterone (DHT; another hormone that is stronger than testosterone) impacts the effectiveness of TRT in the impaired lower limbs and in other tissues after SCI. The researchers hypothesize that TRT will improve muscle and bone in the impaired limbs of men with chronic incomplete SCI and reduce fat mass, and that finasteride (a drug that blocks that blocks a process that changes testosterone to DHT) will influence prostate symptoms but not the musculoskeletal or body composition benefits produced by TRT.",[186,187,188,189,190,191,192,193,33,194,195,196,197,198],"Spinal Cord Injury","Spinal Cord Injuries","Injuries, Spinal Cord","Spinal Cord Contusion","Spinal Cord Trauma","Trauma, Nervous System","Wounds and Injuries","Spinal Cord Compression","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male",[200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,186,239,240,241,242,73,187,191,192,31,33,194,195,196,197,198,243],"Testosterone","Testosterone cypionate","Testosterone enanthate","Testosterone 17 beta-cypionate","Testosterone undecanoate","Methyltestosterone","Testosterone propionate","Dihydrotestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Therapy","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Lipid and Glucose profile","Muscle Strength","5-alpha Reductase","Muscle Mass","Bone Mineral Density","Adipose Tissue","Fat Mass","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Muscle, Skeletal","Bone and Bones","Gait","Walking","Locomotion","Motor Activity","Finasteride","Genital Diseases","Urogenital Diseases","Male Urogenital Diseases","Bone Diseases","Steroids","NOT_YET_RECRUITING","2026-08-03",{"date":247,"type":42},"2026-08-04",{"date":249,"type":22},"2027-10-01",{"date":251,"type":22},"2032-03-31",{"name":253,"class":254},"VA Office of Research and Development","FED",4,{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":18,"minAge":263,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":64,"phases":267,"briefSummary":269,"conditions":270,"keywords":301,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":337},"100355699","phase-1-hsv-g207-in-children-with-recurrent-or-refractory-cerebellar-brain-tumors-100355699","NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* A review of the MRI scan will be necessary to determine if the tumor location and size are such that the patient may be included in the study. The MRI scan must be reviewed and approved by the site neurosurgeon and\u002For study radiologist for enrollment. The following guidelines must be met: Lesion must be ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking. Tumor measurements should be confirmed on the Immunotherapy Response Assessment in Neuro-Oncology (iRANO) form or the institutional MRI report\n* Patients must have fully recovered from acute treatment-related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to the date of G207 administration. All washout intervals below are measured relative to the date of G207 administration.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea) to G207 administration.\n* Monoclonal antibodies: patient must have received the last dose ≥ 21 days prior to G207 administration\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to G207 administration (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥\\>= 7 days).\n* Viral therapy: Patients must have received viral therapy ≥ 3 months prior to G207 administration and must have recovered from all acute toxicities potentially related to the agent\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to G207 administration. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to G207 administration.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to G207 administration.\n* Absolute neutrophil count \\> 1000\u002Fmm3\n* Platelets ≥ 100,000\u002Fmm\\^3\n* Prothrombin time (PT) or partial thromboplastin time (PTT) ≤ 1.3 x control\n* Creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m\\^2 for patients with creatinine levels above institutional normal\n* Total bilirubin ≤ 1.5 mg\u002Fdl\n* Transaminases ≤ 3 times above the upper limits of the institutional norm\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Written informed consent in accordance with institutional and Food and Drug Administration (FDA) guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or central nervous system (CNS) infection ≤ 3 months prior\n* Receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Patient requires an escalation in ongoing systemic corticosteroid therapy within 7 days prior to G207 inoculation or requires ongoing systemic corticosteroid therapy at a dose \\> 2 mg\u002Fday of dexamethasone (or equivalent) at the time of inoculation. For this study, 'systemic corticosteroids' include oral, intravenous, or intramuscular formulations. A single, non-consecutive dose does not constitute exclusion. Physiologic corticosteroid replacement therapy (e.g., hydrocortisone for adrenal insufficiency) is not considered immunosuppressive and does not constitute exclusion\n* Known human immunodeficiency virus (HIV) seropositivity\n* Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone)\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen for this trial\n* Concurrent anticancer or investigational drug","36 Months","22 Years",{"count":266,"type":22},24,[268],"PHASE1","This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,30,31,33,295,296,297,298,299,300],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[302,303,272,304,305,306,307,308,309,310,311,312,313,314,315,316,274,317,318,319,320,321,322,323,324,297,296,325,326,327],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","2026-07-28",{"date":330,"type":42},"2026-07-29",{"date":332,"type":42},"2019-09-12",{"date":334,"type":22},"2027-09-01",{"name":336,"class":49},"M.D. Anderson Cancer Center",3,{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":64,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":50},"100611832","shoulder-health-after-rehabilitation-and-performance-training-100611832","NCT07245706","Shoulder Health After Rehabilitation and Performance Training","Ensuring Shoulder Health as a Key Factor for Long Term Health and Functioning of Manual Wheelchair Users","SHARP","Inclusion Criteria:\n\n* Persons with a paraplegia below T2\n* Manual wheelchair user\n* Age 18 - 70 years\n* At discharge from initial rehabilitation\n\nExclusion Criteria:\n\n* Trauma or surgery of the shoulder with medical indication for immobilization of more than four weeks\n* Constant use of power assistance for the wheelchair\n* Any surgical implants that exclude the participant for MRI assessments of the shoulder\n* Inability to follow the study instructions, e.g., mental health problems, language problems, dementia, claustrophobia (for MRI) etc.\n* Persons with congenital conditions leading to SCI, SCI in the context of palliative care, neurodegenerative disorders, and Guillain-Barré syndrome\n* Pregnancy","70 Years",{"count":348,"type":22},40,[119],"The goal of this study is to investigate the impact of a home-based shoulder strength training on the overall shoulder health in manual wheelchair users, and if the timepoint of such a training makes a difference. The study is focusing on persons with a spinal cord injury in the thoracic or lumbar region of the spine, that have only recently been injured and will soon be discharged from primary rehabilitation.\n\nThe shoulder training will take place either 3 or 12 months after discharge from primary rehabilitation and will be carried out twice a week for 12 weeks.\n\nThere are six measurements occurring every three months, which leads to an overall duration of 15 months. The measurements consist of:\n\n* Questionnaires about independence in daily life, participation, quality of life and physical activity\n* Assessment of shoulder strength, range of motion and function\n* Measurement of the daily wheelchair use during one week via sensors that are fixed to the wheelchair and wrist\n* one further questionnaire at the end of the measurement week about the occurrence of shoulder pain\n\nAdditionally, on four of the six measurement timepoints, a magnet resonance image (MRI) of the shoulder will be taken to assess the shoulder status (pathology, muscle volume and quality).\n\nThough all these measurements the researchers can additionally assess the load of daily life on the shoulders, and how well this matches the preparation during the primary rehabilitation.",[186,33,73,352],"Injury",[354,355,356,357,358,359,360,361],"Shoulder","Wheelchair","Training","Activity of Daily Life","Load","Capacity","Functioning","Monitoring","2026-07-22",{"date":364,"type":42},"2026-07-23",{"date":366,"type":42},"2026-07-16",{"date":368,"type":22},"2029-12",{"name":370,"class":371},"Swiss Paraplegic Research, Nottwil","NETWORK",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":380,"maxAge":381,"enrollmentInfo":382,"targetDuration":384,"studyType":23,"phases":4,"briefSummary":385,"conditions":386,"keywords":395,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":171},"100472474","rett-syndrome-registry-100472474","NCT05432349","Rett Syndrome Registry","Rett Syndrome Real World Data Observational Registry","RSR","Inclusion Criteria:\n\n* Male or female with a pathologic loss of function alteration of MECP2\n\nExclusion Criteria:\n\n* Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication","0 Years","99 Years",{"count":383,"type":22},3000,"5 Years","The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.",[387,388,389,153,390,391,392,393,394,33],"Rett Syndrome","Rett Syndrome, Atypical","Genetic Disease","Intellectual Disability","Neurobehavioral Manifestations","Neurologic Manifestations","Neurologic Disorder","Neurodevelopmental Disorders",[396,397,398,399,400],"Rett syndrome","MECP2","Neurodevelopmental disorder","Registry","Natural History Study","2026-06-26",{"date":403,"type":42},"2026-06-30",{"date":405,"type":42},"2022-08-02",{"date":407,"type":22},"2028-07",{"name":409,"class":49},"International Rett Syndrome Foundation",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":64,"phases":421,"briefSummary":422,"conditions":423,"keywords":429,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":50},"100644654","impact-of-transcutaneous-spinal-stimulation-on-blood-pressure-and-orthostasis-in-spinal-cord-injury-100644654","NCT07674511","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects","(SCI)","Inclusion Criteria:\n\n* Individuals with a SCI ≥ 1 year after injury\n* Injury level ≥ T6 (thoracic level)\n* AIS grade A-C\n* Cardiovascular dysfunction characterized by one or more of the following:\n\n  1. Persistent hypotension (SBP \\\u003C 90mmHg)\n  2. Orthostatic hypotension (OH, a drop of 20\u002F10 mmHg in SBP\u002FDBP within 5 minutes of standing\u002Fupright positioning).\n\nAdditionally, experiencing orthostatic symptoms in daily life and\u002For requiring medication to manage OH.\n\nExclusion Criteria:\n\n* Current illness (e.g., infection, a pressure injury that might interfere with the intervention)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* History of seizures\n* pregnancy\n* Insufficient mental capacity to understand and independently provide consent\n* Deemed unsuitable by the study physician","75 Years",{"count":420,"type":22},10,[119],"The purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury.\n\nThe main questions this study attempts to solve:\n\n1. What are the immediate effects of spinal cord transcutaneous stimulation on BP?\n2. Does stimulation produce lasting improvements in BP regulation and subsequently, daily function?",[187,424,425,194,426,191,427,33,428],"Hypotension","Orthostatic Hypotension","Cardiovascular Diseases","Central Nervous System Disease","Blood Pressure",[430,431,432,433,434],"transcutaneous spinal cord stimulation","spinal stimulations","orthostatic hypotension","blood pressure","neuromodulation","2026-06-24",{"date":437,"type":42},"2026-06-29",{"date":439,"type":22},"2026-09",{"date":441,"type":22},"2028-12",{"name":443,"class":49},"Kessler Foundation",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":64,"phases":454,"briefSummary":455,"conditions":456,"keywords":481,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":337},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":453,"type":22},500,[119],"This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[457,33,458,459,26,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480],"Neurologic Disorders","Neurodegenerative Diseases","Neurological Disorders","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[482,483,26,460,122,484,473,485,464,479,476,486],"Neurologic Disease","Cerebral Vascular Accident","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":401,"type":42},{"date":489,"type":42},"2016-06",{"date":491,"type":22},"2028-07-31",{"name":493,"class":106},"MD Stem Cells",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":64,"phases":504,"briefSummary":505,"conditions":506,"keywords":512,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":521,"locationsCount":50},"100644087","efficacy-and-safety-of-antihypertensive-treatment-with-mobile-stroke-units-in-ultra-early-intracerebral-hemorrhage-100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":503,"type":22},706,[119],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[33,29,426,507,508,509,466,510,26,511],"Vascular Diseases","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage, Hypertensive","Hemorrhagic Stroke, Intracerebral",[513,514,515],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","2026-06-18",{"date":435,"type":42},{"date":519,"type":22},"2026-06",{"date":407,"type":22},{"name":522,"class":49},"Xuanwu Hospital, Beijing",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":531,"sex":18,"minAge":532,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":64,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":50},"100384501","brain-connections-for-arm-movement-after-stroke-100384501","NCT04286516","Brain Connections for Arm Movement After Stroke","Brain Areas That Control Reaching Movements After Stroke: Task-relevant Connectivity and Movement-synchronized Brain Stimulation","CAM","Inclusion Criteria:\n\nInclusion Criteria (control participants):\n\n* Be 45-90 years of age\n* Have adequate language and neurocognitive function to participate in training and testing\n* Be medically stable to participate in the study\n* Be English speaking\n\nInclusion Criteria (participants with stroke):\n\n* Be 45-90 years of age\n* Clinically defined, unilateral, hemiparetic stroke with radiologic exclusion of other possible diagnosis\n* Stroke onset at least 6 months before enrollment\n* Subcortical stroke (ex: internal capsule, deep white matter of posterior frontal lobe)\n* Present with mild to moderate arm dysfunction\n* Be medically stable to participate in the study\n* Be English speaking\n\nExclusion Criteria:\n\n(for both groups)\n\n* Unable to give informed consent\n* Have a serious complicating medical illness that would preclude participation\n* Contractures or orthopedic problems limiting range of joint motion in the potential study arm or other impairments that would interfere with the study activities\n* Visual loss such that the subject would not be able to see the test patterns on the robot computer monitor\n* Unable to comply with requirements of the study\n* Enrollment in another greater-than-minimal risk study\n* Presence of medical condition or implant that prevents safe administration of TMS or MRI\n* Pregnancy",true,"45 Years","90 Years",{"count":535,"type":22},76,[119],"The purpose of this study is to use Transcranial Magnetic Stimulation (TMS) while subjects are making reaching movements in a robotic arm device in order to discover how different brain areas control movement before and after stroke and when these brain areas are most sensitive to TMS.",[26,539,31,33,426],"Brain Disease","2026-05-28",{"date":542,"type":42},"2026-06-02",{"date":544,"type":42},"2020-01-10",{"date":546,"type":22},"2027-06-01",{"name":253,"class":254},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":64,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":50},"100559941","video-call-assisted-assessment-of-acute-stroke-100559941","NCT06570681","Video Call Assisted Assessment of Acute Stroke","Video Call Assisted Assessment of Acute Stroke in Addition to Stroke Scales in a Prehospital Setting: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Suspected stroke within 24 hours from onset (confirmed with Prehospital Stroke 1 decision tool)\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Suspected stroke more than 24 hours ago\n* In-hospital stroke or private transport to hospital\n* Unconsciousness defined as Glasgow Coma Score (GCS) ≤ 8 (as they cannot be rated)",{"count":556,"type":22},512,[119],"This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical technicians can increase feasibility and performance of symptom-based prehospital stroke scales.",[26,29,30,33,507,31],"2026-05-11",{"date":562,"type":42},"2026-05-14",{"date":564,"type":42},"2024-05-27",{"date":566,"type":22},"2026-06-03",{"name":568,"class":49},"University of Southern Denmark",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":418,"enrollmentInfo":575,"targetDuration":4,"studyType":64,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":50},"100539440","deep-brain-stimulation-motor-ventral-thalamus-vopvim-for-restoration-of-speech-and-upper-limb-function-in-people-with-subcortical-stroke-100539440","NCT06303869","Deep Brain Stimulation Motor Ventral Thalamus (VOP\u002FVIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke","Inclusion Criteria:\n\n1. Participants must have suffered a single, ischemic, or hemorrhagic stroke more than 6 months before the time of enrollment with dysarthria as a result.\n2. Participants must be between the ages of 18 and 75 years old. (Participants outside this age range may be at an increased medical risk and have an increased risk of fatigue during testing).\n3. English speaker.\n4. Participant must score ≤ 80% in at least 4 categories of the perceptual speech assessment (speech intelligibility, listener effort, speech naturalness, articulatory precision, speech rate, overall voice quality, and\u002For overall speech severity). OR ≤ 80% in at least 3 categories of the perceptual speech assessment AND ≤ 27 on the Communicative Participation Item Bank.\n\nExclusion Criteria:\n\n1. Patients who refuse participation in the study.\n2. Patients with gross anatomical variances in MR imaging or cerebral vascular accidents involving thalamic and cerebellar areas.\n3. Patients with no clinical condition to undergo DBS implantation or highly dependent on anticoagulation therapy.\n4. Patients who cannot undergo pre-operative MRIs or could not complete the pre-operative assessments.\n5. Participants must not have any serious disease or disorder (ex. neurological condition other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) or cognitive impairments that could affect their ability to participate in this study.\n6. Female participants of child-bearing age must not be pregnant, planning to become pregnant for the next 9 months, or breast feeding.\n7. Participants must not be receiving anticoagulants.\n8. Severe claustrophobia.\n9. Participants must not be on anti-spasticity or anti-epileptic medications for the duration of the study.\n10. Participants who have been deemed inappropriate for participation based upon results from the Brief Symptoms Inventory (BSI-18) and discussions with the Principal Investigator and a study physician\n11. Evaluation to sign consent form score \\<12.\n12. MRI contraindications (excluding subjects who are pregnant, who have metal in any portion of their body, have medical complications, cardiac pacemaker, cochlear implant, aneurysm clip, certain IUDs, or known problems of claustrophobia).\n13. Medications with common cognitive side-effects.\n14. Bleeding disorders or platelet dysfunction (e.g., from regular aspirin usage).\n15. Patients must not have any lesions in the lower motoneuron causing flaccid dysarthria.",{"count":420,"type":22},[119],"The goal of this study is to verify whether the use of deep brain stimulation can improve motor function of the hand and arm and speech abilities for people following a stroke. Participants will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neuro-rehabilitation programs to restore speech and upper limb motor functions in people with subcortical strokes, thereby increasing independence and quality of life.",[26,539,31,33,426],"2026-05-05",{"date":581,"type":42},"2026-05-08",{"date":583,"type":42},"2025-06-20",{"date":368,"type":22},{"name":586,"class":49},"Jorge Gonzalez-Martinez",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":595,"maxAge":596,"enrollmentInfo":597,"targetDuration":4,"studyType":64,"phases":599,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":107},"100522861","study-to-evaluate-the-efficacy-and-safety-of-atnc-mdd-v1tms-with-cognitive-training-in-mild-alzheimers-dementia-100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.","60 Years","85 Years",{"count":598,"type":22},180,[119],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[602,476,30,31,33,458,603,604],"Alzheimer's Disease","Neurocognitive Disorders","Mental Disorder",[606,607,608,476],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":611,"type":42},"2026-04-23",{"date":613,"type":42},"2023-05-15",{"date":615,"type":22},"2027-06-30",{"name":617,"class":106},"Advanced Technology & Communications",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":531,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":64,"phases":628,"briefSummary":629,"conditions":630,"keywords":632,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":647},"100419829","functional-near-infrared-spectroscopy-in-unconscious-patients-100419829","NCT04746820","Functional Near-infrared Spectroscopy in Unconscious Patients","Prognostic Value of Functional Near-infrared Spectroscopy in Unconscious Neurocritical Care Patients- a Prospective Pilot Study","fNIRS","Inclusion Criteria - experimental group:\n\n* Patients of either sex with severe hemorrhagic, ischemic stroke or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation treated at the Institute of Intensive Care Medicine, University Hospital Zurich\n* Unconsciousness (GCS \\\u003C 9) or sedated to the severity of the disease (for the subgroup of patients included in the fNIRS-EEG measurement unconscious patients are defined as not responding to verbal stimuli. The motor response to pain should be one of the following: no response to pain \u002F extensor response \u002F flexor response \u002F localize to pain)\n* Age ≥ 18 years\n* Signed informed consent obtained from legal representative\n* Measurement logistically and technical possible within the first 7 days after admission\n\nInclusion Criteria - control group:\n\n* Subjects of either sex\n* Conscious (GCS = 15)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria - experimental group:\n\n* Patients age \\\u003C 18 years\n* Positive pregnancy test for any female of childbearing potential or breast feeding female\n* Previous auditory complaints or any ear diseases\n* No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)\n* Any history of previous cerebral or brainstem disease\n* Concomitant instable critical illness (e.g. sepsis, multi-organ failure, hemodynamic or respiratory instability)\n* Acute status epilepticus\n* Clinical recovery (GCS ≥ 9) or death before enrolment of the study\n\nExclusion Criteria - control group:\n\n* Subjects age \\\u003C 18 years\n* Positive pregnancy test for any female of childbearing potential or breast feeding female\n* Previous auditory complaints or any ear diseases\n* No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)\n* Any history of previous cerebral or brainstem disease",{"count":627,"type":22},30,[119],"The study design is a single-center prospective pilot study. Hypothesis: Results of cerebral fNIRS examination in unconscious patients with severe hemorrhagic or ischemic stroke in the ICU are congruent with the results of SSEP and AEP. Hence, making it a potential prognostic tool for unconscious ICU patients.\n\nIn a specific subgroup of unconscious patients after cardiac arrest and cardiopulmonary resuscitation the fNIRS measurement is congruent with the results of electroencephalography (EEG).\n\nThe primary purpose of this study is to evaluate the agreement of the results of fNIRS examination to those of evoked potentials and EEG in unconscious ICU patients with severe hemorrhagic, or ischemic strokes or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation.\n\nfNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.\n\nTo compare fNIRS with evoked potentials there are two test phases:\n\n1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP\n2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP\n\nTo avoid biases the following has to be considered:\n\n* The timing of the measurements plays an important role. A time difference between compared measurements can influence the outcome significantly due to deterioration or recovery of the neuronal network during the time gap. Therefore, fNIRS and evoked potentials will be measured simultaneously.\n* If the compared measurement methods are conducted by the same researcher the possibility of bias is high. Hence, two different researcher will conduct each one measurement without knowing the results of each other during the measurement.",[33,631],"Healthy Subjects",[633,634,635,636,637,638],"severe cerebral hemorrhage","ischemic stroke","unconscious neurocritical care patients","functional near-infrared spectroscopy","evoked potentials","electroencephalography",{"date":640,"type":42},"2026-04-27",{"date":642,"type":42},"2020-01-15",{"date":644,"type":22},"2026-12-31",{"name":646,"class":49},"Emanuela Keller",2,{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":654,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":64,"phases":658,"briefSummary":659,"conditions":660,"keywords":664,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":678},"100607166","intra-arterial-thrombolysis-for-acute-ischemic-stroke-with-medium-vessel-occlusion-100607166","NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":657,"type":22},282,[119],"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[26,29,30,33,507,661,662,663],"Ischemic Stroke","Infarction","Medium Vessel Occlusion",[665,666,26,667,668],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":671,"type":42},"2026-04-16",{"date":673,"type":42},"2026-01-06",{"date":675,"type":22},"2030-05-01",{"name":677,"class":49},"The Second Hospital of Anhui Medical University",6,{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":684,"acronym":4,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":596,"enrollmentInfo":686,"targetDuration":4,"studyType":64,"phases":688,"briefSummary":689,"conditions":690,"keywords":707,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":724,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":728,"locationsCount":730},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease",{"count":687,"type":22},60,[66],"This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[691,74,692,693,458,151,694,695,33,696,697,698,699,700,701,702,703,704,705,706],"Neuromuscular Disease","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Nerve Disorders","Nervous System Disease","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[708,699,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723],"TTR","Polyneuropathy","NTLA-2001","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR",{"date":671,"type":42},{"date":726,"type":42},"2024-11-22",{"date":136,"type":22},{"name":729,"class":106},"Intellia Therapeutics",14,{"id":732,"slug":733,"hasResults":12,"nctId":734,"briefTitle":735,"officialTitle":736,"acronym":737,"eligibilityCriteria":738,"healthyVolunteers":12,"sex":18,"minAge":739,"maxAge":381,"enrollmentInfo":740,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":742,"conditions":743,"keywords":744,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":750,"lastUpdatePostDateStruct":751,"startDateStruct":753,"completionDateStruct":755,"leadSponsor":757,"locationsCount":50},"100416112","collection-of-biological-samples-from-patients-with-rare-neurological-diseases-100416112","NCT04698421","Collection of Biological Samples From Patients With Rare Neurological Diseases","Prospective Collection of Biological Samples From Patients With Rare Neurological Diseases","EXPLAINEUR","Inclusion Criteria:\n\n* all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and\u002For central nervous system symptoms.\n* Social coverage up to date.\n\nExclusion Criteria:\n\n* Patients with neurological damage from which the autoimmune character can be excluded.\n* Known anemia and hemoglobin \\\u003C10 g \u002F dl\n* Patients under protective supervision (guardianship, curators)\n* Pregnant or breastfeeding woman","6 Years",{"count":741,"type":22},1000,"The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.",[33],[745,746,747,748,749],"autoimmune encephalitis","paraneoplastic neurological syndrome","myasthenia","paraneoplastic cerebellar degeneration","rare neuropathologies with known\u002Fsuspected autoimmune origin","2026-03-16",{"date":752,"type":42},"2026-03-19",{"date":754,"type":42},"2020-10-12",{"date":756,"type":22},"2030-09-03",{"name":758,"class":49},"University Hospital, Toulouse",{"id":760,"slug":761,"hasResults":12,"nctId":762,"briefTitle":763,"officialTitle":764,"acronym":765,"eligibilityCriteria":766,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":767,"enrollmentInfo":768,"targetDuration":4,"studyType":64,"phases":770,"briefSummary":771,"conditions":772,"keywords":775,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":783,"lastUpdatePostDateStruct":784,"startDateStruct":785,"completionDateStruct":787,"leadSponsor":788,"locationsCount":50},"100337803","treating-depression-on-a-day-to-day-basis-development-of-a-tool-for-physicians-based-on-a-smartphone-application-100337803","NCT03678194","Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application","Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)","SMART","Inclusion Criteria:\n\n* Age between 18 and 65 years;\n* Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;\n* Patients started their antidepressant treatment less than 5 days before inclusion;\n* Patient treated in an outpatient setting;\n* Patient informed of the diagnosis of his disease;\n* Informed patient with written consent.\n\nExclusion Criteria:\n\n* A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;\n* A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;\n* Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;\n* Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);\n* Non-comprehension of the French language","65 Years",{"count":769,"type":22},200,[119],"Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.",[773,774,30,31,33],"Depression","Psychiatric Disorder",[773,776,777,778,779,780,781,782],"Smartphone","Relapse prevention","Mobile support system","eHealth","Ecological","Randomized","Multicentric","2026-03-13",{"date":750,"type":42},{"date":786,"type":42},"2020-10-14",{"date":644,"type":22},{"name":789,"class":790},"Centre Hospitalier Charles Perrens, Bordeaux","OTHER_GOV",{"id":792,"slug":793,"hasResults":12,"nctId":794,"briefTitle":795,"officialTitle":795,"acronym":796,"eligibilityCriteria":797,"healthyVolunteers":531,"sex":18,"minAge":798,"maxAge":115,"enrollmentInfo":799,"targetDuration":4,"studyType":64,"phases":801,"briefSummary":802,"conditions":803,"keywords":810,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":835,"lastUpdatePostDateStruct":836,"startDateStruct":838,"completionDateStruct":840,"leadSponsor":842,"locationsCount":50},"100617877","slowing-cognitive-decline-in-alpha-synucleinopathies-by-enhancing-physical-activity-100617877","NCT07324330","Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity","ALPHA-FIT","Inclusion Criteria:\n\niRBD:\n\n* Age: 50-80 years\n* Polysomnographically confirmed diagnosis of iRBD\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nHealthy controls:\n\n* Age: 50-80 years\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nExclusion Criteria:\n\niRBD:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n\nHealthy controls:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n* clinically diagnosed iRBD","50 Years",{"count":800,"type":22},130,[119],"α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.\n\nThe aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.\n\nEighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the \"Deutsches Zentrum für Neurodegenerative Erkrankungen\" (DZNE) Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, magnetic resonance imaging (MRI) and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06993142). In addition, selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-are planned to be synthesized into a meta-analysis.",[804,805,458,806,31,807,33,808,30,809],"Parkinson Disease","Prodromal Stage","Basal Ganglia Diseases","Synucleinopathies","Cerebral Disorder","Parkinsonian Disorders",[811,812,813,814,815,816,817,818,819,820,821,822,823,824,825,826,827,828,829,830,467,831,832,833,834],"intervention","movement","iRBD","prodromal parkinson's","non-pharmacologic","alpha-synucleinopathy","biomarker","cognitive decline","executive function","MRI","lifestyle","prevention","RCT","motor decline","smartphone","smartwatch","accelerometer","scalable","prodromal","PD","Lewy-body","MSA","multiple system atrophy","dementia","2026-01-14",{"date":837,"type":42},"2026-01-16",{"date":839,"type":42},"2025-12-04",{"date":841,"type":22},"2029-12-01",{"name":843,"class":49},"University Hospital, Bonn",{"id":845,"slug":846,"hasResults":12,"nctId":847,"briefTitle":848,"officialTitle":849,"acronym":850,"eligibilityCriteria":851,"healthyVolunteers":531,"sex":18,"minAge":418,"maxAge":4,"enrollmentInfo":852,"targetDuration":4,"studyType":64,"phases":853,"briefSummary":854,"conditions":855,"keywords":856,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":857,"lastUpdatePostDateStruct":858,"startDateStruct":859,"completionDateStruct":861,"leadSponsor":863,"locationsCount":50},"100534314","effects-of-the-cotid-community-occupational-therapist-in-dementia-program-and-usual-occupational-therapy-care-on-recurrence-of-falls-at-12-months-in-elderly-people-with-neurocognitive-disorders-who-had-been-hospitalized-for-falls-after-their-return-home-100534314","NCT06237218","Effects of the COTID (Community Occupational Therapist in Dementia) Program and Usual Occupational Therapy Care on Recurrence of Falls at 12 Months in Elderly People With Neurocognitive Disorders Who Had Been Hospitalized for Falls, After Their Return Home","Effets du Programme COTID (Community Occupational Therapist in Dementia) et d'Une Prise en Soins ergothérapique Habituelle Sur la récidive de Chutes à 12 Mois de Personnes âgées Atteintes de Troubles Neurocognitifs et Ayant été hospitalisées Pour Chute, après Leur Retour à Domicile","ErgoFalls","Inclusion Criteria:\n\n* Male or female, at least 75 years old\n* Living at home (excluding nursing home or long-term care facilities)\n* Hospitalized for fall\n* Presenting major mild to moderate dementia (MMSE \\> 16)\n* Accompanied by a caregiver with sufficient presence to meet study procedures: at investigator's discretion at the investigator's discretion\n* Having given free, informed and written consent signed by the patient\n* Whose caregiver has given free, informed consent written and signed by him\u002Fherself\n* Affiliated or beneficiary of social security\n\nExclusion Criteria:\n\n* With serious, life-threatening pathology(ies) or in palliative care\n* Participating in an educational fall program on the theme of falls, run by an occupational therapist by an occupational therapist\n* Receiving regular occupational therapy treatment on the day of inclusion (day care daily hospitalization)\n* Participating in a clinical research protocol have an impact on the occurrence of a fall (at the investigator's discretion)\n* Not matching with the fall definition from Kellogg's definition of a fall (loss of consciousness, sudden onset of paralysis paralysis or epileptic seizure)\n* Presenting a very significant post-fall syndrome:\n\nscore of 4\u002F4 on the \"Get-up early\" questionnaire\n\n* unable to read or write\n* Participant under legal guardianship (curator, guardian, legal protector)\n* Dementia with rapid neurocognitive degeneration degeneration with frontal and language impairment (at the investigator's discretion).",{"count":535,"type":22},[119],"This project will enable optimization of specific carried out by occupationist for older adults discharged from hospital for falls:\n\n* on the environmental dimension at the participant's home\n* on the involvement of the caregiver since they are also involved in the care of the patient\n* on the recurrence of falls and rehospitalizations in order to improve the quality of life by reassuring the elderly person when traveling\n* on limiting loss of autonomy and staying at home. The occupational therapist will entrust the caregiver with a support role. The participant will feel more involved in the participant's care (thus reducing the feeling of helplessness). His actions will allow him to strengthen his sense of competence and will prevent him from physical and psychological exhaustion.",[33],[476],"2026-01-12",{"date":835,"type":42},{"date":860,"type":42},"2024-07-29",{"date":862,"type":22},"2027-03-08",{"name":864,"class":49},"University Hospital, Limoges",{"id":866,"slug":867,"hasResults":12,"nctId":868,"briefTitle":869,"officialTitle":870,"acronym":4,"eligibilityCriteria":871,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":767,"enrollmentInfo":872,"targetDuration":4,"studyType":64,"phases":874,"briefSummary":875,"conditions":876,"keywords":890,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":892,"lastUpdatePostDateStruct":893,"startDateStruct":894,"completionDateStruct":896,"leadSponsor":898,"locationsCount":50},"100619143","amylin-induced-migraine-attacks-without-aura-100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":873,"type":22},21,[119],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[877,878,30,33,31,392,879,880,881,882,883,884,209,885,886,887,888,889],"Headache Disorders, Primary","Headache Disorders","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Migraine Disorders","Headache","Pain","Peptide Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[891,882,883,888],"Migraine","2026-01-05",{"date":835,"type":42},{"date":895,"type":22},"2026-02",{"date":897,"type":22},"2028-10-30",{"name":899,"class":49},"Danish Headache Center",{"id":901,"slug":902,"hasResults":12,"nctId":903,"briefTitle":904,"officialTitle":905,"acronym":4,"eligibilityCriteria":906,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":767,"enrollmentInfo":907,"targetDuration":4,"studyType":64,"phases":908,"briefSummary":909,"conditions":910,"keywords":913,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":892,"lastUpdatePostDateStruct":915,"startDateStruct":916,"completionDateStruct":917,"leadSponsor":918,"locationsCount":50},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":873,"type":22},[119],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[911,30,878,33,31,392,879,880,912,883,884,209,885,886,887,888,889],"Headache Disorders, Secondary","Post-Traumatic Headache",[914,883,888],"Post-traumatic headache",{"date":835,"type":42},{"date":895,"type":22},{"date":441,"type":22},{"name":899,"class":49},{"id":920,"slug":921,"hasResults":12,"nctId":922,"briefTitle":923,"officialTitle":923,"acronym":924,"eligibilityCriteria":925,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":926,"targetDuration":4,"studyType":64,"phases":927,"briefSummary":928,"conditions":929,"keywords":931,"overallStatus":244,"whyStopped":4,"lastUpdateSubmitDate":892,"lastUpdatePostDateStruct":942,"startDateStruct":944,"completionDateStruct":946,"leadSponsor":948,"locationsCount":4},"100618712","gravity-stroke-system-for-recanalization-of-large-vessel-occlusion-strokes-100618712","NCT07335185","Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","GRASSROOT Reg","Inclusion Criteria:\n\n1. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.\n2. Subject has been or will be treated with Supernova and\u002For Neutron devices as the initial device used to remove the thrombus\n3. Subject is willing to participate in a 90-day follow-up visit.\n\nExclusion Criteria:\n\n* Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.",{"count":383,"type":22},[119],"Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.",[26,661,29,30,31,33,930],"Vascular Disease",[932,933,934,464,935,936,937,938,939,940,26,941],"Mechanical Thrombectomy","Brain","Brain Clot","Brain Infarction","Neurovascular Intervention","Revascularization","Reperfusion","Stent Retriever","Supernova","Gravity Medical Technology",{"date":943,"type":42},"2026-01-13",{"date":945,"type":22},"2026-01-01",{"date":947,"type":22},"2030-12-31",{"name":949,"class":106},"Gravity Medical Technology, INC"]